Gerrit Dispersyn, Dr. Med. Sc.
President and Chief Executive Officer
Dr. Gerrit Dispersyn joined Phio Pharmaceuticals Corp. in April 2017. Dr. Dispersyn is an accomplished leader in clinical, product and business development. He most recently served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporation. In this role, Gerrit was responsible for Integra’s global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integra’s Senior Management Leadership team, and several of the company’s core teams for M&A projects. Dr. Dispersyn has also been involved in Integra’s research and business activities related to Human Cells, Tissues, and Cellular and Tissue based Products (HCT/Ps), an experience that could be beneficial for Phio's newly added focus on immuno-oncology and cell therapy. Prior to that role, he was the Vice President, Product Development & Portfolio Management for Barrier Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. The company was a spin-out of Johnson & Johnson, and currently part of GlaxoSmithKline. There he led planning and implementation of all aspects of R&D operations and strategy; scientific, competitive and business intelligence; and alliance management. Dr. Dispersyn is the founder of Ingress, LLC, a consultancy company providing R&D and clinical operations support to start-up companies, supporting several pharmaceutical drug development programs. Dr. Dispersyn holds a Dr. Med. Sc. (Ph.D. in Medical Sciences), from the Faculty of Medicine, Maastricht University, Maastricht, the Netherlands, a post-graduate degree in Biomedical Imaging, and a M.Sc. in Biochemistry, both from the University of Antwerp, Belgium.
James Cardia, Ph.D.
VP of Business Operations
James Cardia, Ph.D., is the Vice President of Business Operations at Phio Pharmaceuticals, with over 10 years’ experience in biotechnology. During his tenure at Phio, Dr. Cardia’s group was responsible for the discovery and optimization of “self-delivering” rxRNAs (sd-rxRNAs®) as well as the development and characterization of RXI-109, a promising anti-fibrotic agent currently in development for the treatment of both dermal and retinal scarring. He has contributed to numerous publications and patent applications. Dr. Cardia has a Ph.D. in chemistry from Boston College and received postdoctoral training in the Department of Chemistry and Chemical Biology at Harvard University.
VP of Finance and Administration
Caitlin Kontulis has been with Phio Pharmaceuticals since April 2012. Prior to Phio, Ms. Kontulis was the Controller of, at the time, Galena Biopharma, Inc. where she played a central role in the spin-out of Phio as a stand-alone public company from Galena. Previously, Caitlin began her career in the audit practice of PricewaterhouseCoopers in Boston, Massachusetts. Ms. Kontulis received her Masters in Accounting from Northeastern University and a Bachelor’s degree with a major in Accounting from Bryant University. Caitlin is a licensed certified public accountant in the state of Massachusetts.